Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.34 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065744 | 0.94 | CA1 (0.41) | BCL6CA1CA2CA7CA13 | |
| SCHEMBL1673854 | 0.84 | PIP4K2A (0.47) | BCL6CA1CA2CA7CA13 | |
| SCHEMBL4267411 | 0.75 | TTBK1 (0.44) | BCL6EGFRERBB2MAPTKDM4E | |
| SCHEMBL4268627 | 0.74 | EGFR (0.44) | BCL6CA1CA2CA7CA13 | |
| SCHEMBL4275266 | 0.73 | TTBK1 (0.52) | BCL6EGFRERBB2MAPTHTT | |
| SCHEMBL4260577 | 0.73 | BCL6 (0.47) | BCL6CA1CA2CA7CA13 | |
| SCHEMBL4274133 | 0.72 | EGFR (0.55) | EGFRERBB2MAPTMAPK1POLB | |
| SCHEMBL4276211 | 0.72 | EGFR (0.55) | EGFRERBB2MAPTHTTPIP4K2A | |
| SCHEMBL4264958 | 0.71 | KDR (0.54) | BCL6EGFRERBB2MAPTHTT | |
| SCHEMBL4269335 | 0.71 | EGFR (0.52) | BCL6EGFRERBB2KDM4EABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7838525-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1644357-B9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2010-03-24 | — | — | EP | disclosed |
| CN-100509798-C | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-07-08 | — | — | CN | disclosed |
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1599468-B1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARM INC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | disclosed |
| CN-1823056-A | Trisubstituted aryl and heteroaryl derivatives as modulatorsof metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARM INC (US) | 2006-08-23 | — | — | CN | disclosed |
| EP-1644357-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005007647-A9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | BCL6 2232/4885CA1 4617/4885CA2 3725/4885 |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | CYP7A1, CYP27A1, SULT2A1 | BCL6 2373/4885CA1 4719/4885CA2 4081/4885 |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | BCL6 2232/4885CA1 4617/4885CA2 3725/4885 |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | UGT1A1, GPR119, UGT1A3 | BCL6 2170/4885CA1 4514/4885CA2 3142/4885 |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | CYP27A1, CYP11B2, CYP11B1 | BCL6 2249/4885CA1 4832/4885CA2 2970/4885 |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | BCL6 2465/4885CA1 4857/4885CA2 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.